Papers
Yedier-Bayram O, Cingöz A, Yilmaz E, Aksu AC, Esin B, Pınarbaşı-Değirmenci N, Cavga AD, Dedeoğlu B, Cevatemre B, Syed H, Philpott M, Cribbs AP, Oppermann U, Lack, NA, Acilan C, Onder TT and Bagci-Onder T. “Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer.” bioRxiv 2024.04.16.587277; doi: https://doi.org/10.1101/2024.04.16.587277. (Submitted: Experimental & Molecular Medicine). Download
Lingadahalli S, Ersoy Fazlioglu B, Altintas UB, Cingöz A, Tekoglu E, Yu IPL, Dikbas UM, Andomat H, Kulac I, Morova T, Xiao K, Gleave M, Fazli L, Cejas P, Cherkasov A, Zwart W, Long H, Collins C, Bagci-Onder T, Lack NA. “HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI/SNF complex.” bioRxiv (2023), 2023.09.04.556101. https://doi.org/10.1101/2023.09.04.556101. (Submitted: Nature Cancer) Download
Kayabolen A, Sahin GN, Seker F, Cingoz A, Isik B, Acar S, Solaroglu I, Wakimoto H, Cahill D, Cribss A, Oppermann U, Bagci-Onder T. “Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma”. bioRxiv, 2020.11.26.400234; https://doi.org/10.1101/2020.11.26.400234. (Revision: Cell Death and Disease) Download.
Ozyerli-Goknar E, Kala EY, Aksu AC, Bulut I, Cingöz A, Niuzamuddin S, Biniossek M, Seker-Polat F, Morova T, Aztekin C, Kung S, Syed H, Tuncbag N, Gonen M, Philpott M, Cribbs A, Acilan C, Timmers HTM, Lack NA, Onder TT, Bagci-Onder T. “Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival”. Cell Commun Signal., 2023 Nov 16;21(1):328. doi: 10.1186/s12964-023-01335-6 Download
Çavdar S., Kose B, Altinoz D, Soyler G, Cingöz A, Gurses İA, Ozkan M, Asliyurek H, Cakir H. “Lymphatic Vessels Accompanying Dorsal and Basal Dural Sinuses in the Human Brain”. Journal of Chemical Neuroanatomy, 2023, 134, 102357.
Gunduz H, Acari A, Cetin S, Almammadov T, Pinarbasi-Degirmenci N, Dirak M, Cingoz A, Kilic E, Bagci-Onder T, Kolemen S. “Directing chemiluminescent dioxetanes to mitochondria: A cationic luminophore enables in vitro and in vivo detection of cancer cells upon enzymatic activation”. Sensors & Actuators: B. Chemical 383,133574, 2023. https://doi.org/10.1016/j.snb.2023.133574.
Yedier-Bayram O, Gökbayrak B, Aksu AC, Cavga AD, Kayabolen A, Kala EY, Karabiyik G, Cingöz A., Günsay R, Morova T, Uyulur F, Lack, NA, Onder TT and Bagci-Onder T. "EPIKOL, a chromatin-focused CRISPR/Cas9 library identifies cancer-specific epigenetic vulnerabilities". Cell Death Dis 13, 710 (2022)Download
Dogan NO, Bozuyuk U, Erkoc P, Cingoz A, Seker F, Karacakol A, Nazeer MA, Sitti M, Bagci-Onder T, Kizilel S. “Parameters Influencing the Transfection Efficiency of PEGylated Chitosan Nanoparticles: Experimental and Modeling Approach”. Adv. NanoBiomed Res., 2021.
Cingöz A, Ozyerli-Goknar E, Morova T, Seker F, Selvan M, Gumus ZH, Bhere D, Shah K, Bagci-Onder T. “Generation of TRAIL-resistant cell line models reveals adoption of different mechanisms of acquired resistance and re-sensitization”. Oncogene, 2021. Download
Kayabolen A, Sahin GN, Seker F, Cingoz A, Isik B, Acar S, Solaroglu I, Wakimoto H, Cahill D, Cribss A, Oppermann U, Bagci-Onder T. “Combination of epigenetic enzyme inhibitors, GSKJ4 and Belinostat, reveals efficacy in IDH1 mutant gliomas”. bioRxiv, 2020.11.26.400234; Download
Senbabaoglu F, Aksu AC, Cingoz A, Seker F, Kahya Z, Solaroglu I, Bagci-Onder T. “Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma”. Front. Neurosci, 2020, Dec 17;14:578316.Download
Sur-Erdem I, Muslu K, Pinarbasi N, Altunbek M, Seker F, Cingoz A, Kahraman M, Culha M, Solaroglu I, Bagci-Onder T. “TRAIL conjugated silver nanoparticles sensitize glioblastoma cells to TRAIL by regulating CHK1 in the DNA repair pathway”. Neurol. Res. 2020. 42(12):1061-1069.Download
Saraç H, Morova T, Pires E, McCullagh J, Kaplan A, Cingöz A, Bagci-Onder T, Onder T, Kawamura A, Lack N. “Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer”. Oncogene, Dec 10, 2019. Download
Ozyerli-Goknar E, Sur-Erdem I, Seker F, Cingöz A, Kayabolen A, Kahya Z, Uyulur F, Gezen M, Erman B, Gonen M, Oppermann U, Bagci-Onder T. “The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma”. Cell Death Dis., 10 (12), 894. Nov 26, 2019. doi: https://doi.org/10.1038/s41419-019-2107-y Download
Seker F, Cingoz A, Sur-Erdem I, Ergüder N, Erkent A, Uyulur F, Selvan M, Gümüş ZH, Gönen M, Bayraktar H, Wakimoto H, Bagci-Onder T. “Identification of SERPINE1 as a regulator of glioblastoma cell dispersal with transcriptome profiling”. Cancers, Oct. 2019., 11(11), 1651.
doi: https://doi.org/10.3390/cancers11111651 Download
Ezgi Kaya-Aksoy, Ahmet Cingoz, Filiz Senbabaoglu, Fidan Seker, Ilknur Sur-Erdem, Alisan Kayabolen, Tolga Lokumcu, Gizem Nur Sahin, Sercin Karahuseyinoglu, Tugba Bagci-Onder. "The pro-apoptotic Bcl-2 family member Harakiri (HRK) induces cell death in glioblastoma multiforme". Cell Death Discovery ( 2019) 5:64. https://doi.org/10.1038/s41420-019-0144-z Download
Kurt IC, Sur I, Kaya E, Cingoz A, Kazancioglu S, Kahya Z, Toparlak OD, Senbabaoglu F, Kaya Z, Ozyerli E, Karahüseyinoglu S, Lack NA, Gümüs ZH, Onder TT, Bagci-Onder T., “KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL”. Cell Death Dis. 2017 Jun 29;8(6):e2897. DOI: 10.1038/cddis.2017.288.
Erkoc P, Cingoz A, Bagci-Onder T, Kizilel S. "Quinacrine Mediated Sensitization of Glioblastoma (GBM) cells to TRAIL through MMP-sensitive PEG Hydrogel Carriers". Macromolecular Bioscience, 2016 Oct 20. doi: 10.1002/mabi.201600267.
Senbabaoglu F, Cingoz A, Kaya E, Kazancioglu S, Lack N, Acilan C, Bagci-Onder T. "Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme". Cancer Biology and Therapy, 17, pg: 546-557, 2016.
Uzer B, Toker SM, Cingoz A, Bagci-Onder T, Gerstein G, Maier HJ, Canadic D. “An exploration of plastic deformation dependence of cell viability and adhesion in metallic implant materials”. Journal of the Mechanical Behavior of Biomedical Materials, 60, pp.177–186, 2016.